| Q35075430 | A subset of mouse colonic goblet cells expresses the bitter taste receptor Tas2r131 |
| Q34961511 | ABCD of the phosphodiesterase family: interaction and differential activity in COPD |
| Q77337355 | Adenosine 5'-diphosphate as a factor in platelet aggregation induced by human plasma remnant lipoproteins |
| Q46353150 | Antenatal betamethasone therapy augments isoproterenol and prostaglandin E2-mediated relaxation of preterm ovine pulmonary veins |
| Q40850350 | Assays of cyclic nucleotides. A review of current techniques |
| Q48113134 | Assessing protein-ligand binding modes with computational tools: the case of PDE4B. |
| Q72649434 | Biochemical and pharmacological characterization of cyclic nucleotide phosphodiesterase in airway epithelium |
| Q46349904 | Bronchoprotective effects of KF-19514 and cilostazol in guinea pigs in vivo. |
| Q35323516 | CNP-pGC-cGMP-PDE3-cAMP Signal Pathway Upregulated in Gastric Smooth Muscle of Diabetic Rats |
| Q70837871 | Ca2+ and cyclic adenosine monophosphate involvement in radiographic contrast medium-induced renal vasoconstriction |
| Q42505107 | Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes |
| Q42985106 | Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel |
| Q74348132 | Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats |
| Q36410391 | Clinical pharmacology of Cilomilast |
| Q33542536 | Comparative tolerability and efficacy of treatments for impotence |
| Q41012548 | Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors |
| Q56925438 | Cyclic AMP-phosphodiesterases inhibitor improves sodium excretion in rats with cirrhosis and ascites |
| Q46828383 | Cyclic GMP and cGMP-binding phosphodiesterase are required for interleukin-1-induced nitric oxide synthesis in human articular chondrocytes |
| Q34047351 | Cyclic nucleotide analogs as biochemical tools and prospective drugs |
| Q35194780 | Cyclic nucleotide phosphodiesterases in pancreatic islets |
| Q34047795 | Cyclic nucleotide phosphodiesterases: relating structure and function |
| Q52534390 | Decreases in cAMP phosphodiesterase activity in hepatocytes cultured with herbimycin A due to cellular microtubule polymerization related to inhibition of tyrosine phosphorylation of alpha-tubulin. |
| Q57994792 | Development of a recombinant cell-based system for the characterisation of phosphodiesterase 4 isoforms and evaluation of inhibitors |
| Q44488010 | Developmental change in isoproterenol-mediated relaxation of pulmonary veins of fetal and newborn lambs |
| Q41184616 | Differential expression of cGMP-inhibited cyclic nucleotide phosphodiesterases in human hepatoma cell lines |
| Q77144696 | Effect of a cGMP-specific phosphodiesterase inhibitor on retinal function |
| Q44330705 | Effect of electromagnetic field on cyclic adenosine monophosphate (cAMP) in a human mu-opioid receptor cell model |
| Q54674021 | Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts. |
| Q46584657 | Effects of sildenafil citrate on hepatic function and regeneration in normal and alcohol-fed rats |
| Q74234057 | Effects of sildenafil on human penile blood vessels |
| Q51400905 | Effects of the phosphodiesterase-III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible patients. |
| Q72716902 | Effects of two vasodilatory phosphodiesterase inhibitors on bradykinin-induced permeability increase in the hamster cheek pouch |
| Q42708971 | Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity |
| Q71230144 | Effects of various phosphodiesterase-inhibitors, forskolin, and sodium nitroprusside on porcine detrusor smooth muscle tonic responses to muscarinergic stimulation and cyclic nucleotide levels in vitro |
| Q24672678 | Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor |
| Q28594618 | Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice |
| Q78155403 | Increased nitroglycerin-induced relaxation by genistein in rat aortic rings |
| Q35874526 | Influence of S-nitrosothiols and nitrate tolerance in the rat gastric fundus |
| Q37388865 | Inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina |
| Q37807016 | Insights into GPCR pharmacology from the measurement of changes in intracellular cyclic AMP; advantages and pitfalls of differing methodologies |
| Q77425131 | Interaction of cyclic GMP and cyclic AMP during neutrophil migration: involvement of phosphodiesterase type III |
| Q28354227 | Involvement of cyclic AMP systems in morphine physical dependence in mice: prevention of development of morphine dependence by rolipram, a phosphodiesterase 4 inhibitor |
| Q40852001 | Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses |
| Q35044409 | Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1) |
| Q41628588 | Models of persistent pulmonary hypertension of the newborn (PPHN) and the role of cyclic guanosine monophosphate (GMP) in pulmonary vasorelaxation |
| Q36627684 | Modulation of oxazolone-induced hypersensitivity in mice by selective PDE inhibitors |
| Q51603501 | Molecular Docking Study Based on Pharmacophore Modeling for Novel PhosphodiesteraseIV Inhibitors. |
| Q24530596 | Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3 |
| Q30795209 | Molecular cloning of DNA encoding a calmodulin-dependent phosphodiesterase enriched in striatum |
| Q28115169 | Multiple splice variants of phosphodiesterase PDE4C cloned from human lung and testis |
| Q39446761 | Neuroprotective actions of dipyridamole on cultured CNS neurons. |
| Q50510406 | Nitric oxide (NO)-dependent but not NO-independent guanylate cyclase activation attenuates hypoxic vasoconstriction in rabbit lungs. |
| Q41628574 | Nitric oxide and pregnancy |
| Q41836594 | Nitric oxide and prostaglandins potentiate the liver regeneration cascade |
| Q77893382 | OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells |
| Q34364468 | PDE4 cAMP-specific phosphodiesterases |
| Q40729067 | PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels |
| Q45304562 | Parathyroid hormone-related protein-mediated responses in pulmonary arteries and veins of newborn lambs |
| Q30045366 | PfPDE1, a novel cGMP-specific phosphodiesterase from the human malaria parasite Plasmodium falciparum |
| Q37384252 | Phosphodiesterase 3 inhibitors suppress oocyte maturation and consequent pregnancy without affecting ovulation and cyclicity in rodents |
| Q34118218 | Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil |
| Q46521491 | Phosphodiesterase IV inhibitors synergistically potentiate relaxation induced by forskolin in guinea-pig trachea |
| Q41708863 | Phosphodiesterase isozymes: molecular targets for novel antiasthma agents |
| Q35140096 | Phosphodiesterase type 5 (PDE5) inhibitors |
| Q42161201 | Photoaffinity labelling of cyclic GMP-binding proteins in human platelets |
| Q44238752 | Prostaglandins E2 and I2 cause greater relaxations in pulmonary veins than in arteries of newborn lambs |
| Q54112607 | Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn lambs with persistent pulmonary hypertension. |
| Q24530028 | Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca2+/calmodulin-stimulated cAMP phosphodiesterase |
| Q34070572 | Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family |
| Q77465118 | Regulation of proteoglycan and hyaluronan synthesis by elevated level of intracellular cyclic adenosine monophosphate in peritubular cells from immature rat testis |
| Q44111212 | Relaxation induced by milrinone and rolipram in human penile arteries and veins. |
| Q40306163 | Restoration of the cAMP second messenger pathway enhances cardiac preservation for transplantation in a heterotopic rat model |
| Q37609062 | Roflumilast and aquaporin-2 regulation in rat renal inner medullary collecting duct |
| Q41478113 | Role of adenosine as a modulator of synaptic activity in the central nervous system |
| Q73788122 | Role of metabotropic glutamate receptors in the depression of GABA-mediated depolarization of frog primary afferent terminals |
| Q48002841 | Role of nitric oxide in cardiac beta-adrenoceptor-inotropic response |
| Q37681576 | Sildenafil Can Affect Innate and Adaptive Immune System in Both Experimental Animals and Patients. |
| Q43826566 | Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase |
| Q42724290 | Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase |
| Q28115585 | Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3) |
| Q41448032 | Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells |
| Q35827477 | Tadalafil pharmacokinetics in healthy subjects |
| Q38205932 | Temporal and spatial regulation of cAMP signaling in disease: role of cyclic nucleotide phosphodiesterases. |
| Q27642525 | The Crystal Structure of AMP-Bound PDE4 Suggests a Mechanism for Phosphodiesterase Catalysis, |
| Q24533566 | The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. |
| Q28217688 | The antidepressant and antiinflammatory effects of rolipram in the central nervous system |
| Q44318890 | The effect of chronic renal failure on phosphodiesterase inhibitor-induced relaxation responses in rabbit cavernosal strips |
| Q35874169 | The effect of isoenzyme-selective PDE inhibitors on methacholine-induced contraction of guinea-pig and rat ileum |
| Q28115926 | The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram |
| Q41291629 | The normal pulmonary vascular transition at birth. |
| Q27641624 | Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity |
| Q47806493 | Transmembrane signaling in periodontal mesenchymal cells: the linkage between stimulus and response |
| Q37082594 | Treating COPD with PDE 4 inhibitors. |
| Q70939374 | Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension |
| Q44371425 | Type IV phosphodiesterase inhibition improves cardiac contractility in endotoxemic rats |
| Q36736800 | Use of a yeast expression system for the isolation and analysis of drug-resistant mutants of a mammalian phosphodiesterase |
| Q36690703 | Zaprinast accelerates recovery from established acute renal failure in the rat |
| Q43969485 | cAMP and cGMP do not mediate the vasorelaxation induced by iodinated radiographic contrast media in isolated swine renal arteries |
| Q35709584 | cAMP detection methods in HTS: selecting the best from the rest |
| Q41030925 | cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. |
| Q34244951 | cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action |